Ken Fisher’s Anika Therapeutics ANIK Stock Holding History

Ken Fisher’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-34,494	Closed	-$324K	–	1022
2025 Q3	$324K	Hold	34,494	–	–	﹤0.01%	871
2025 Q2	$365K	Hold	34,494	–	–	﹤0.01%	843
2025 Q1	$518K	Hold	34,494	–	–	﹤0.01%	779
2024 Q4	$568K	Hold	34,494	–	–	﹤0.01%	756
2024 Q3	$852K	Sell	34,494 -4,126	-11%	-$107K	﹤0.01%	678
2024 Q2	$978K	Hold	38,620	–	–	﹤0.01%	684
2024 Q1	$981K	Hold	38,620	–	–	﹤0.01%	690
2023 Q4	$875K	Sell	38,620 -2,105	-5%	-$43.6K	﹤0.01%	708
2023 Q3	$759K	Sell	40,725 -81,469	-67%	-$1.69M	﹤0.01%	793
2023 Q2	$3.17M	Sell	122,194 -5,063	-4%	-$135K	﹤0.01%	596
2023 Q1	$3.65M	Sell	127,257 -5,756	-4%	-$171K	﹤0.01%	580
2022 Q4	$3.94M	Buy	133,013 +13,622	+11%	+$387K	﹤0.01%	556
2022 Q3	$2.84M	Buy	119,391 +19,483	+20%	+$448K	﹤0.01%	520
2022 Q2	$2.23M	Hold	99,908	–	–	﹤0.01%	520
2022 Q1	$2.51M	Buy	99,908 +29,321	+42%	+$894K	﹤0.01%	519
2021 Q4	$2.53M	Buy	70,587 +34,575	+96%	+$1.38M	﹤0.01%	535
2021 Q3	$1.53M	Buy	36,012 +3,151	+10%	+$130K	﹤0.01%	558
2021 Q2	$1.42M	Sell	32,861 -290	-0.9%	-$12.4K	﹤0.01%	565
2021 Q1	$1.35M	Buy	33,151 +7,111	+27%	+$270K	﹤0.01%	568
2020 Q4	$1.18M	Sell	26,040 -2,878	-10%	-$109K	﹤0.01%	578
2020 Q3	$1.02M	Sell	28,918 -7,234	-20%	-$261K	﹤0.01%	562
2020 Q2	$1.36M	Sell	36,152 -4,644	-11%	-$153K	﹤0.01%	532
2020 Q1	$1.18M	Sell	40,796 -4,113	-9%	-$166K	﹤0.01%	514
2019 Q4	$2.33M	Sell	44,909 -35,491	-44%	-$2.06M	﹤0.01%	468
2019 Q3	$4.41M	Buy	80,400 +10	+0%	+$513	﹤0.01%	449
2019 Q2	$3.27M	Buy	80,390 +11,187	+16%	+$408K	﹤0.01%	479
2019 Q1	$2.09M	Sell	69,203 -5,021	-7%	-$172K	﹤0.01%	518
2018 Q4	$2.5M	Buy	74,224 +3,546	+5%	+$128K	﹤0.01%	492
2018 Q3	$2.98M	Sell	70,678 -20,203	-22%	-$798K	﹤0.01%	483
2018 Q2	$2.91M	Sell	90,881 -12,106	-12%	-$499K	﹤0.01%	501
2018 Q1	$5.12M	Sell	102,987 -8,707	-8%	-$492K	0.01%	413
2017 Q4	$6.02M	Buy	111,694 +5,978	+6%	+$331K	0.01%	395
2017 Q3	$6.13M	Buy	105,716 +24,812	+31%	+$1.3M	0.01%	377
2017 Q2	$3.99M	Buy	80,904 +10,751	+15%	+$495K	0.01%	403
2017 Q1	$3.05M	Buy	70,153 +10,919	+18%	+$521K	﹤0.01%	387
2016 Q4	$2.9M	Sell	59,234 -34,481	-37%	-$1.59M	0.01%	388
2016 Q3	$4.48M	Buy	93,715 +35,996	+62%	+$1.78M	0.01%	365
2016 Q2	$3.05M	Hold	57,719	–	–	0.01%	419
2016 Q1	$2.79M	Buy	57,719 +43,595	+309%	+$1.77M	0.01%	438
2015 Q4	$539K	Buy	+14,124	New	+$540K	﹤0.01%	565

Other funds holding ANIK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ken Fisher's ANIK Position: Q4 2025 in Review

Ken Fisher sold out of Anika Therapeutics (ANIK) in Q4 2025, closing a stake of 34,494 shares — an estimated $324K sold.

Ken Fisher first reported a position in ANIK in Q4 2015 and held it in 40 quarters. The position peaked at $6.13M in Q3 2017. 126 funds tracked by Wall St. Rank hold ANIK as of Q4 2025.

Ken Fisher reported no remaining Anika Therapeutics position as of Q4 2025 after selling out during the quarter.
Ken Fisher sold 34,494 Anika Therapeutics shares in Q4 2025, an estimated $324K.
Ken Fisher first reported a position in Anika Therapeutics in Q4 2015 and held it in 40 quarters.
Ken Fisher's Anika Therapeutics position peaked at $6.13M in Q3 2017.
126 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2025.

Based on Fisher Asset Management's 13F filing for Q4 2025, filed 9 Feb 2026.